Jonathan Kagan

Chairman of the Board

Jonathan has been a member of the Synexis Board of Directors since February 2008 serving as Chairman since 2013.  Mr. Kagan is a Managing Principal of Corporate Partners. Previously, Mr. Kagan was a Managing Director of Corporate Partners I, which he joined in 1990, and of Centre Partners Management LLC, which managed the Centre Capital funds. He began his career in the investment banking division of Lazard in 1980 and became a General Partner in 1987. At Lazard, Mr. Kagan helped head the corporate finance and capital markets areas. He is or has been a member of the board of directors of a number of NYSE- and NASDAQ-listed companies and private companies. Mr. Kagan received a D.Litt. and M.A. (1st Hon.) from Oxford University and an A.B., summa cum laude and Phi Beta Kappa, from Harvard College

 

Harlan Batrus

Director

Harlan Batrus is the Synexis founding investor after several 2007 presentations by chemical engineer, Jim Lee.  In 2008, Harlan recruited private equity investors Jonathan Kagan, John Myers, and Charles Craig as early participants.

Mr. Batrus served as Chairman of the Board of Synexis from 2008 to 2013, before requesting that Jon Kagan succeed him.  Harlan worked at Lehman Brothers, Morgan Stanley and Lazard.  He was a Lazard Partner from 1982 to 2007 in charge of the Fixed Income Department.  He was the 1988 founding investor of Ryan Labs Asset Management and served as Chairman until 2015. In April 2015, Ryan Labs merged into Sun Life of Toronto, Canada.  He received advice from Jon Kagan on the transaction.

Harlan graduated from The Wharton School at Penn.  He serves on the Cardiovascular Council for the Hospital of the University of Pennsylvania.  He is a board member of the Committee to Reduce Infection Deaths (RID) based in New York City.  His office is at Ryan Labs Asset Management located at 500 Fifth Avenue in Manhattan.

David Jefferds

Director

David Jefferds, CFA is Co-Founder of DealVector, a bondholder communications platform and registry that augments the DTC infrastructure of finance for over 1000 issuers, investors, banks, custodians and broker-dealers. In the last year DealVector has worked with market participants to facilitate over $150 billion in consent solicitation efforts. David was formerly Head of Investments at LCM Advisors overseeing portfolio management and investment staff for a global strategy exceeding $500 million. His career has focused on investing in and trading less liquid assets, particularly private companies and structured credit vehicles. He began his career at Lehman Brothers, where he was a Vice President, trading fixed income and commodity derivatives. He is a cum laude graduate of Princeton University and Harvard Law School.

Jamie Kempner

Director

Mr Kempner joined the Synexis Board of Directors in July 2016. He is currently the President of LSH Partners, independent investment banking firm. Mr. Kempner began his career at Lazard, in 1983 and was named a General Partner in 1993. Mr. Kempner has been involved in banking and capital markets transactions and managed Lazard’s Corporate Finance department from 1995-1998. His most recent role was as Senior Advisor in the general industrials banking group, with emphasis on companies in the Transportation and Logistics industries. Mr. Kempner also served on the Underwriting and Private Placement Committees of Lazard. Mr. Kempner advised the Special Committee of Overseas America on its sale to OSG, advised UTI on its Initial Public Offering, Navios Maritime on its sale to International Shipping Enterprises, SuperValu on its acquisition and sale of Total Logistics, New Breed on its sale to Warburg, Pincus, Heidmar on its sale to Morgan Stanley Capital Group, the Special Committee of Swift Transportation on its acquisition of Central Refrigerated and Cardinal Logistics on its sale to Centrebridge. Outside of the Transportation Industry, Mr. Kempner has advised Intersections Inc. (NASDAQ=INTX), on its Initial Public Offering, MasterCraft on its sale to TRP and Charlesbank and FuelCell Energy (NASDAQ=FCEL) on its acquisition of Global Thermoelectric. He is an Advisory Board Member and on the Finance Committee of Mount Sinai Health Systems, a Board Member of LoebsCrunch, LLC (private condiment company), a Board Member of NuLabel Technologies, Inc. (private activateable chemistries company), and a board member of Synexis LLC (private healthcare company). Mr. Kempner is also a Trustee of the James Loring Johnson 1944 Trust. Mr. Kempner received a B.A. from Yale University and an M.B.A. from Harvard University.

Stuart Kinder

Director

Stuart Kinder works at a major US investment bank where he runs the Refined Products and Natural Gas Liquids trading businesses.  Over a fifteen-year career in investment banking, he has built several highly successful trading teams in fixed income and commodities for a number of banks.  Prior to his career on Wall Street, Mr. Kinder was an Infantry Captain in the United States Army with service in Desert Shield/Desert Storm.  He is a graduate of the US Army Airborne, Air Assault and Ranger schools.  Mr. Kinder holds a BS in Computer Science from West Point and an MBA from the University of Chicago Booth School of Business.

James Lee

Founder – Director

Jim is the company founder and is the inventor of Dry Hydrogen Peroxide Gas technology.  He is a West Point Graduate, and was a field grade officer in the Army Chemical Corps throughout the latter days of the Cold War during which he served in key command and staff positions.  Jim has a master’s degree from the University of Virginia in Chemical Engineering and also taught at West Point from 1993 to 1997, where he directed the Academy’s largest academic course.  Upon leaving the Army, Jim became the leading chemical, biological, radiological, and nuclear anti-terrorism consultant in the private sector; and was a full-time consultant for AIG from 2005 to 2006.  Jim is also a state-Licensed Professional Chemical Engineer.

Sanford Morhouse

Director

Mr Morhouse has served on the Board of Synexis since 2008. He is a lawyer at Schulte Roth and Zabel based in New York. His primary focuses is in the areas of corporate and real estate finance. His principal clients include major pension funds, investment advisors and fund sponsors, and his practice involves the creation of, and investments in, private and public investment vehicles and the representation of portfolio companies and properties acquired thereby.

He also spent time at Dewey & LeBoeuf, LLP, where, at various times over his career at a predecessor firm, Dewey Ballantine LLP, he chaired the Real Estate and Private Equity Groups, co-chaired the firm’s Corporate Department, served on the firm’s Executive Committee and co-chaired the firm’s Management Committee. He was recognized in Chambers USA as a leader in the field of Private Equity: Fund Formation and Best Lawyers in America as a leader in the field of Real Estate Law. He received his B.A. from Williams College and his J.D. from Columbia Law School.

John Myers

Director

Mr Myers has served on the Synexis Board since 2008. Mr. Myers completed 38 years of service at General Electric, retiring in September 2006 as President and CEO of GE Asset Management (GEAM). At GEAM he was responsible for approximately $200 billion in assets under management for clients including GE’s pension funds, 401(k) plans, mutual funds and insurance companies as well as for more than 200 external institutional clients. More than 80% of GEAM’s assets were internally managed with multi-strategy capabilities and a significant focus on alternatives. Mr. Myers’s GE career spanned 37 years beginning in 1970 at GE’s Financial Management Program, then offshore assignments in Germany and Italy, and returning to the US in GE’s operating businesses. In 1981, he was appointed Deputy Treasurer of the company, named a GE Group Manager of Finance in 1984, and joined GEAM in 1986 as Executive Vice President with responsibility for fixed income, private equity, venture capital and real estate. He was named President and CEO in 1996.

After retirement from GE, Mr. Myers continued his interest in the investment business by joining Angelo, Gordon, & Co. as a Senior Advisor and Partner and joining the Aurora Capital Group as a member of its Executive Board. He is on the Board of Directors of The Pebble Beach Company and also serves on the Advisory Board of Academy Securities.

Mr. Myers serves on several not-for profit boards including Damon Runyon Cancer Research Foundation, Wagner College Board of Trustees, BuildOn, Hospital for Special Surgery Spine Care Institute, the Diocese of Bridgeport Cathedral Elementary School Cluster and American Corporate Partners, a veteran mentoring organization.

Mr. Myers was a Lieutenant in the U.S. Navy, and served two tours of duty in Vietnam as a Line Officer.  Mr. Myers graduated from Wagner College with a B.S. in Mathematics.

Eric Schlote

CEO

Eric Schlote was hired as the CEO of Synexis in August 2015 and has served on the Synexis Board of Directors since August of 2016. Prior to joining Synexis, Eric was Global Vice President of Sales at Idev Technologies (acquired by Abbott Labs). While at Idev Eric was responsible for launching several new products in various worldwide markets as well as hiring and managing the global sales team. Prior to Idev, Eric served as Director of US sales at Foxhollow Technologies (IPO 2005) where he was directly responsible for hiring and managing the medical device business to over 150 million in annual US sales. Before joining Foxhllow, Eric held management positions with various successful medical device companies. Eric has B.S. Degree from Missouri State University.

Management Team

Eric Schlote

James Lee

Russ Stephens

Chris Raney

Jeff Castille

Douglas Bosma

CEO/Director

Founder

VP Business Development/Strategic Alliances

VP Sales

VP Sales – Sports

SVP

Dry Hydrogen Peroxide (DHP) is  generally effective against any organism that is susceptible to other forms of Hydrogen Peroxide.  Although the Synexis Biodefense System has been effective against every species of dry microbe on which it has been tested, Synexis LLC makes no claim of total disinfection or decontamination of all forms of bacteria, viruses, fungi, mold, and new resistant strains. Synexis LLC is continuously testing our systems against a wide spectrum of microbial threats. Please view our data sheets in the Resources section for current test results of the Synexis Biodefense Systems.  Exclusion of an organism from our test data does not imply inefficacy.  As we continue microbial testing, new results will be posted. If your organization is interested in performing tests against a specific microbe or environmental condition, please contact us.